Should Moderate FMR Should Be Treated With M-TEER? Experts Duke It Out

Why It Matters

The decision will shape treatment pathways for a large, high‑risk patient cohort and influence guideline revisions and device market dynamics.

Key Takeaways

• Anker cites IIa guideline to consider M‑TEER for moderate FMR
• RESHAPE‑HF2 showed benefit regardless of MR severity, but subgroup unclear
• Stone stresses lack of randomized evidence for moderate FMR treatment
• COAPT proved strong benefit in severe MR; moderate data limited
• Trials must define moderate FMR criteria and limit GDMT crossover

Pulse Analysis

The controversy over M‑TEER in moderate functional mitral regurgitation reflects a broader shift in heart‑failure management toward earlier interventional strategies. European heart‑failure guidelines already grant a class IIa recommendation to consider transcatheter repair in symptomatic patients, regardless of regurgitation severity, while the iCARDIO Alliance offers a weaker suggestion for moderate disease. Proponents argue that the procedural risk profile of MitraClip devices is low and that early correction could blunt the progressive remodeling that drives mortality in this population.

Evidence from recent trials paints a nuanced picture. RESHAPE‑HF2 enrolled a mixed cohort of 3+ and 4+ MR patients and demonstrated reductions in heart‑failure hospitalization and cardiovascular death across the board, yet subgroup analyses failed to show a statistically significant interaction with MR severity. By contrast, COAPT, which focused almost exclusively on severe MR, reported a dramatic survival advantage, whereas MITRA‑FR showed modest or no benefit. These divergent outcomes stem partly from differing inclusion criteria—especially effective regurgitant orifice area thresholds—and underscore the difficulty of extrapolating severe‑MR data to moderate cases.

Looking ahead, the field is poised for a dedicated randomized trial targeting moderate FMR. Such a study must standardize severity definitions, enforce consistent guideline‑directed medical therapy, and prevent crossover that could dilute treatment effects. If successful, it could expand the therapeutic window for M‑TEER, drive new reimbursement models, and stimulate further innovation in percutaneous valve technologies. Until then, clinicians will balance the promise of early intervention against the uncertainty of unproven benefit, guided by individual patient risk profiles and evolving guideline language.